beromun 1mg powder for solution for infusion vials
boehringer ingelheim ltd - tasonermin - powder for solution for infusion - 1mg
praxbind 2.5g50ml solution for infusion vials
boehringer ingelheim ltd - idarucizumab - solution for infusion - 50mg/1ml
vargatef 100mg capsules
boehringer ingelheim ltd - nintedanib esilate - capsule - 100mg
vargatef 150mg capsules
boehringer ingelheim ltd - nintedanib esilate - capsule - 150mg
ofev 100mg capsules
boehringer ingelheim ltd - nintedanib esilate - capsule - 100mg
ofev 150mg capsules
boehringer ingelheim ltd - nintedanib esilate - capsule - 150mg
onduarp
boehringer ingelheim international gmbh - telmisartan - hypertension - cardiovascular system - treatment of essential hypertension in adults:add on therapyonduarp is indicated in adults whose blood pressure is not adequately controlled on amlodipine.replacement therapyadult patients receiving telmisartan and amlodipine from separate tablets can instead receive tablets of onduarp containing the same component doses.
giotrif
boehringer ingelheim international gmbh - afatinib - carcinoma, non-small-cell lung - antineoplastic agents - giotrif as monotherapy is indicated for the treatment ofepidermal growth factor receptor (egfr) tki-naïve adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating egfr mutation(s);locally advanced or metastatic nsclc of squamous histology progressing on or after platinum-based chemotherapy.
jardiance
boehringer ingelheim international gmbh - empagliflozin - diabetes mellitus, type 2; heart failure; renal insufficiency, chronic - drugs used in diabetes - type 2 diabetes mellitusjardiance is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered in addition to other medicinal products for the treatment of diabetesfor study results with respect to combinations of therapies, effects on glycaemic control, and cardiovascular and renal events, and the populations studied, see sections 4.4, 4.5 and 5.1. of the annex.heart failurejardiance is indicated in adults for the treatment of symptomatic chronic heart failure. chronic kidney diseasejardiance is indicated in adults for the treatment of chronic kidney disease.
cyltezo
boehringer ingelheim international gmbh - adalimumab - hidradenitis suppurativa; arthritis, psoriatic; psoriasis; crohn disease; arthritis, juvenile rheumatoid; uveitis; arthritis, rheumatoid; colitis, ulcerative; spondylitis, ankylosing - immunosuppressants - please refer to section 4.1 of the summary of product characteristics in the product information document.,